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Abstract
Background: The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-a2a/RBV therapies
on HCV viral decline in HIV/HCV genotype 3 co-infected patients during the first weeks of treatment.
Methods: Plasma HCV viral decline was analyzed between baseline and weeks 1, 2 and 4 in two groups of treatment-naı¨ve
HCV genotype 3 patients with HIV co-infection. The Standard Dose Group (SDG) included patients who received Peg-IFN at
180 mg/per week with a weight-adjusted dose of ribavirin; Low-Dose Group (LDG) patients received Peg-IFN at 135 mg/per
week with 800 mg/day ribavirin. The effect of IL28B genotype on HCV viral decline was evaluated in both groups. HCV viral
decline was analyzed using a multivariate linear regression model.
Results: One hundred and six patients were included: 48 patients in the SDG and 58 in the LDG. HCV viral decline for
patients in the LDG was less than for those in the SDG (week 1:1.7260.74 log10 IU/mL versus 1.7860.67 log10 IU/mL,
p = 0.827; week 2:2.360.89 log10 IU/mL versus 3.0161.02 log10 IU/mL, p = 0.013; week 4:3.5261.2 log10 IU/mL versus
4.0961.1 log10 IU/mL, p = 0.005). The linear regression model identified the Peg-IFN/RBV dose as an independent factor for
HCV viral decline at week 4.
Conclusions: Our results showed that HCV viral decline was less for patients in the low-dose group compared to those
receiving the standard dose. Until a randomized clinical trial is conducted, clinicians should be cautious about using lower
doses of Peg-IFN/RBV in HIV/HCV genotype 3 co-infected patients.
Citation: Rivero-Jua´rez A, Lopez-Cortes LF, Camacho A, Torres-Cornejo A, Pineda JA, et al. (2012) Differences in HCV Viral Decline between Low and Standard-
Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients. PLoS ONE 7(11): e48959. doi:10.1371/journal.pone.0048959
Editor: Wenzhe Ho, Temple University School of Medicine, United States of America
Received August 16, 2012; Accepted October 2, 2012; Published November 8, 2012
Copyright:  2012 Rivero-Jua´rez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partly supported by grants from the Fundacio´n Progreso y Salud, Consejerı´a de Salud de la Junta de Andalucı´a (grants for health
research projects: refs. 0036/2010, PI-0247-2010 and PI-0208 and 0124/2008) and the Spanish Health Ministry (ISCIII-RETIC RD06/006, and projects PI10/0164 and
PI10/01232). AR is the recipient of a research extension grant from the Fundacio´n Progreso y Salud, Consejerı´a de Salud de la Junta de Andalucı´a (Reference AI-
0011-2010); JAP is the recipient of extension grant from the Instituto de Salud Carlos III (grant number Programa-I3SNS). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: AR has received consulting fees from Bristol-Myers Squibb, Abbott, Gilead, Roche and Boehringer Ingelheim. JAP has received consulting
fees from GlaxoSmithKline, Bristol-Myers Squibb, Abbott, Gilead, Merck Sharp & Dohme, Janssen-Cilag and Boehringer Ingelheim. LFLC has received funds for
speaking at symposia organized on behalf of Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithkline, Gilead Sciences, MSD, Janssen-Cilag S. A., and Viiv
Healthcare. They have received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbott and Boehringer Ingelheim, and
lecture fees from GlaxoSmithKline, Roche, Abbott, Bristol-Myers Squibb, Boehringer Ingelheim and Schering-Plough. The remaining authors have no conflicts of
interest to declare. This does not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials.
* E-mail: ariveror@gmail.com
Introduction
The best determinant of response to hepatitis C virus (HCV)
treatment using pegylated-interferon (Peg-IFN) in combination
with ribavirin (Peg-IFN/RBV) is the HCV genotype itself. Rates of
sustained virological response (SVR) in genotypes 1 or 4 HCV
patients co-infected with HIV vary between 17 and 46% in
different studies, while for genotype 3 HCV/HIV co-infected
patients these values range between 43 and 71% [1,2]. The higher
treatment response rate for genotype 3 HCV patients is due the
higher rate of HCV viral clearance in the first weeks of therapy
[3]. On the other hand, it has also been observed that HCV
genotype 3 patients progress more rapidly to advanced stages of
liver fibrosis and hepatic steatosis and are at a significantly higher
risk of developing hepatocellular carcinoma [4–6]. For these
reasons, patients infected with HCV genotype 3 constitute a
population which requires the early implementation of treatment.
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The current recommended treatment for genotype 3 HCV/
HIV co-infected patients is 48 weeks with Peg-IFN-a2a or Peg-
IFN-a2b (180 mg/kg and 1.5 mg/kg per week, respectively)
combined with ribavirin (weight-adjusted) [7,8]. However, neither
duration of treatment nor drug dose have been clearly optimized.
For genotype 3 HCV monoinfected patients, the recommended
length of treatment is 24 weeks, and even 12–16 weeks for patients
achieving rapid virological response (RVR), and lower doses of
Peg-IFN/RBV have been shown to achieve similar SVR rates to
the standard dose [9–11]. However, because of the different
responses to treatment, more rapid progression to liver fibrosis,
interaction with antiretroviral treatment drugs and immunological
characteristics, the results cannot be extrapolated to HIV/HCV
co-infected patients [12,13].
Early viral kinetics gives clinicians valuable information about
the outcome of HCV treatment. Several studies have shown that
HCV viral decay in the first weeks after start of treatment can help
identify which patients will respond to treatment and which will
not [14–19]. HCV viral decline during the first weeks of treatment
is also useful for analyzing the effects of different drug doses,
including the impact on HCV clearance.
The aim of this study was to analyze the different impacts of
standard and lower-than- standard dose Peg-IFN-a2a/RBV
therapy on HCV viral decline in HIV/HCV genotype 3 co-
infected patients during the first weeks after start of treatment.
Methods
Patients, Study Design and Treatment Regimen
Two groups of HIV/HCV genotype 3 co-infected patients who
were naı¨ve to HCV treatment were included in the study.
The Standard Dose Group (SDG) included patients enrolled in
a prospective study designed to evaluate the efficacy of a treatment
strategy for chronic hepatitis C genotype 3, who were adminis-
tered Peg-IFN-a2a at 180 mg/per week combined with a weight-
adjusted dose of ribavirin (1000 mg/day for ,75 kg, 1200 mg/
day for $75 kg); length of treatment (24 or 48 weeks) was
determined according to whether or not RVR was achieved.
The Low Dose Group (LDG) included patients enrolled in an
open-label, single-arm clinical trial (Reference: NCT00553930)
evaluating the efficacy of Peg-IFN-a2a at a dose of 135 mg/per
week combined with a daily ribavirin dose of 800 mg.
Ethical Aspects
The SDG study was designed and carried out according to the
Helsinki declaration and was approved by the Ethics Committee
of the Hospital Reina Sofia of Cordoba. (Reference:
NCT00553930). All patients were informed and signed an
informed consent form before participating in the study. The
protocol of the LDG trial and supporting CONSORT checklist
are available as supporting information; see [20]. The study
protocol was approved by the Agencia Espan˜ola del Medicamento
and a central ethics committee (Comite´ Autono´mico de Ensayos
Clı´nicos, Consejerı´a de Salud, Junta de Andalucı´a). The study was
conducted according to the Declaration of Helsinki and current
guidelines on Good Clinical Practices. This trial is registered at
NIH register (ClinicalTrials.gov: NCT00553930) and EMEA
(NuEudraCT: 2007-000814-35).
Data Collection
Host, clinical and virological characteristics were collected.
Fibrosis stage was determined by biopsy or liver transient
elastography (FibroScanH, Echosen. Paris). Significant fibrosis
was defined as a METAVIR fibrosis score of F2–F4 in liver biopsy
or a liver stiffness value of $8.9 kPa [21].
Virological Evaluation
Plasma HCV RNA load measurements were conducted at
baseline and weeks 1, 2 and 4, using a quantitative PCR assay
(Cobas TaqMan, Roche Diagnostic Systems Inc., Pleasanton, CA,
USA) and using a detection limit of 15 IU/mL. Viral load was
expressed as log10IU/mL.
IL28B Genotyping
DNA was extracted using the automated MagNA Pure DNA
extraction method (Roche Diagnostics Corporation. Indianapolis,
IN 46250, USA). Single nucleotide polymorphism (SNP)
rs129679860, located 3 kilobases upstream of the IL28B, and in
strong linkage disequilibrium with a non-synonymous coding
variant in the IL28B gene (213A.G, K70R; rs81031142), was
genotyped. Genotyping was carried out using a custom TAQMAN
assay (Applied Biosystems, Foster City, California, USA) on DNA
isolated from whole blood samples, on a Stratagene MX3005
thermocycler with MXpro software (Stratagene, La Jolla, Califor-
nia, USA), following the manufacturer’s instructions. The
researchers responsible for genotyping were blinded to other
patient data. The IL28B genotype was defined as CC or non-CC
(TT/CT).
Statistical Analysis
Continuous variables were expressed as mean 6 standard
deviation or median (Q1–Q3) and were analyzed by the Student’s
t test, Mann-Whitney U-test or Kruskal-Wallis test. Categorical
variables were expressed as numbers of cases (percentage).
Frequencies were compared using the x2 test or Fisher’s exact
test. Significance was defined as a p value of less than 0.05. Plasma
HCV RNA decline, according to SDG and LDG dose, was
analyzed from baseline to weeks 1, 2 and 4. The effect of IL28B
genotype on HCV viral decline was also analyzed in both
treatment groups. Patients presenting an undetectable HCV viral
load at any time point during the study were excluded when
calculating reduction of HCV RNA levels at a later time. A
multivariate linear regression model was used to analyze HCV
viral decline between baseline and the various time points. In
addition, two linear regression models of HCV viral decline from
baseline to the different time points were analyzed according to
treatment group. The analysis was performed using the SPSS
statistical software package, version 18.0 (IBM Corporation,
Somers, NY, USA).
Results
One hundred and six HIV/HCV genotype 3 co-infected
patients were included in the study. Forty-eight (45.3%) patients
were included in the SDG and 58 (54.7%) in the LDG. The
baseline population characteristics of the two groups are shown in
Table 1.
HCV Viral Decline According to Treatment Group
HCV viral decline of patients given the lower dose treatment
was less than for those in the SDG, at weeks 2 and 4 after start of
treatment, although not at week 1 (week 1:1.7260.74 log10 IU/
mL versus 1.7860.67 log10 IU/mL, p = 0.827; week 2:2.360.89
log10 IU/mL versus 3.0161.02 log10 IU/mL, p = 0.013; week
4:3.5261.2 log10 IU/mL versus 4.0961.1 log10 IU/mL, p = 0.005)
(Figure 1). The multivariate linear regression models of factors
associated with HCV viral decline at weeks 1, 2 and 4 showed that
Low versus Standard-Dose of HCV Treatment
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the steeper and sustained HCV viral decline from week 2 to week
4 was associated with a lower baseline HCV RNA viral load and
with patients in the SDG (Table 2). IL28B-CC and HCV viral
decline were not associated.
Table 1. Baseline Population Characteristics.
Characteristic SDG LDG P
N 48 58
Male. N (%) 39 (81.2) 51 (87.9) 0.379
Age (years). Mean (SD) 40.4 (8.86) 43.6 (5.37) 0.612
Use of HAART, n (%) 45 (93.7) 52 (89.6) 0.588
AIDS diagnosis in the past, n (%) 13 (27.1) 10 (17.2) 0.213
Baseline CD4 count (cells/mm3).
mean (SD)
479.9 (234.7) 496.5 (266.4) 0.743
PIDU, n (%) 43 (89.5) 48 (82.7) 0.454
HCV baseline viral load (log10 IU/
mL). Mean (SD)
5.72 (0.75) 5.51 (1) 0.247
Liver fibrosis stage F2–F4. n (%) 32 (66.6) 33 (56.9) 0.277
Liver Cirrhosis. n (%) 12 (25) 21 (36.2) 0.253
ALT (IU/L). Mean (SD) 80.3 (47.7) 91 (57) 0.409
AST (IU/L). Mean (SD) 65.5 (35.2) 79.9 (33) 0.541
Total fasting cholesterol (mg/dL).
Mean (SD)
156.1 (40.4) 147 (37) 0.325
LDL cholesterol (mg/dL). Mean (SD) 86.8 (33.6) 76 (29) 0.147
Platelet count (103/mL). Mean (SD) 183 (65) 176 (68) 0.654
IL28B-CC genotype. N (%) 13 (43.4){ 24 (53.3){ 0.409
Standard drug dose group (SDG); low drug dose group (LDG); human
immunodeficiency virus (HIV); highly active antiretroviral treatment (HAART);
acquired immunodeficiency syndrome criteria in the past (AIDS); previous
intravenous drug user (PIDU); hepatitis C virus (HCV); interleukin 28B (IL28B).
{Available for 30 patients. {Available for 45 patients.
doi:10.1371/journal.pone.0048959.t001
Figure 1. Mean HCV viral decline between baseline and weeks 1, 2 and 4 for the standard drug dose group (SDG) and the low drug
dose group (LDG).
doi:10.1371/journal.pone.0048959.g001
Table 2. Multivariate linear regression model of HCV viral
decline between baseline and weeks 1, 2 and 4 after start of
treatment.
HCV decline at week 1
Factor Condition B P
Treatment Group SDG 20.175 0.327
Baseline HCV viral load (log10
IU/mL)
0.059 0.637
Significant liver fibrosis stage Yes 20.247 0.676
IL28B genotype Non-CC 0.296 0.113
HCV decline at week 2
Factor Condition B P
Treatment Group SDG 0.274 0.037
Baseline HCV viral load 0.329 0.026
Significant liver fibrosis stage Yes 20.113 0.340
IL28B genotype Non-CC 20.103 0.551
HCV decline at week 4
Factor Condition B P
Treatment Group SDG 0.335 0.025
Baseline HCV viral load 0.339 0.002
Significant liver fibrosis stage Yes 20.180 0.092
IL28B genotype Non-CC 20.041 0.791
adjusted coefficient (B), hepatitis C virus (HCV), interleukin 28B (IL28B), standard
drug dose group (SDG). R2 = 0.327.
doi:10.1371/journal.pone.0048959.t002
Low versus Standard-Dose of HCV Treatment
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HCV Viral Decline According to Treatment Group and
IL28B Genotype
Among SDG patients, there were no differences of HCV viral
decline by IL28B genotype at week 1 (1.8260.91 log10 IU/mL
versus 1.7460.87 log10 IU/mL, p = 0.852), week 2 (361.1 log10
IU/mL versus 3.0861.09 log10 IU/mL, p = 0.807) or week 4
(4.1460.84 log10 IU/mL versus 4.1761.06 log10 IU/mL,
p = 0.938) (Figure 2A). Similarly, no differences of HCV viral
decline by IL28B genotype were found among LDG patients at
week 1 (2.0760.47 log10 IU/mL versus 1.4261.08 log10 IU/mL,
p = 0.071), week 2 (2.4660.86 log10 IU/mL versus 2.0361.35 log10
IU/mL, p = 0.257) or week 4 (3.4460.94 log10 IU/mL versus
3.2661.01 log10 IU/mL, p = 0.573) (Figure 2B).
Among IL28B-CC genotype patients, HCV viral decline was
greater in the SDG than in the LDG at weeks 2 and 4, but not at
week 1 (week 1: p = 0.362; week 2: p = 0.051; week 4: p = 0.033).
Likewise, HCV viral decline was greater among SDG patients
carrying the IL28B non-CC genotype than among their LDG
non-CC counterparts, at weeks 2 and 4 (week 1: p = 0.343; week 2:
p = 0.034; week 4: p = 0.037).
Rapid Virological Response Rate
HCV viral load for 6 (5.6%) patients could not be evaluated at
week 4. Of the remaining 100 patients, 66 (66%) achieved RVR:
thirty-five (72.9%) in the SDG, and 31 (59.6%) in the LDG
(p = 0.174). RVR rates by treatment group and IL28B genotype
are shown in Table 3.
Discussion
In our study, HCV viral decay of patients who received low-
dose Peg-IFN/RBV treatment was less during the first weeks of
treatment than for those receiving the standard Peg-IFN/RBV
dose. This finding suggests that a lower Peg-IFN/RBV dose has
less antiviral activity than the standard dose.
High viral decline during the first weeks of treatment leads to a
high RVR rate [3]. Several factors have been identified as
determining HCV viral decay [3,21]. Our study found that HCV
viral decay correlated with Peg-IFN dose in HIV/HCV genotype
3 co-infected patients, with steeper viral decline from week 2 to
week 4 in the SDG compared to the LDG. Our study also found
that the dose of Peg-IFN administered during treatment was the
most important factor affecting HCV viral decline in these
patients. RVR rates in our study were also higher in the SDG
compared to the LDG (72.9% versus 59.6%), although the
differences between the two groups were not statistically signifi-
cant. This point should be interpreted with caution, since a better
powered cohort might be required for statistically significant
associations, due to the high RVR rate among HCV genotype 3
patients.
Reducing the dose in drug-based HCV therapy for mono-
infected HCV genotype 3 patients has been studied in various
clinical trials. Firstly, reducing the dose of Peg-IFNa2a from
180 mg/per week to 135 mg/per week was shown to give similar
RVR and SVR rates [9,10]. Secondly, SVR rates did not differ
significantly according to whether a lower daily dose or a weight-
adjusted dose of ribavirin was used [22–24]. A reduced dose of
both drugs is, therefore, applicable to this patient population.
However, in HCV genotype 3 patients co-infected with HIV, a
low-dose Peg-IFN/RBV combination would have a considerable
impact, in terms of a high SVR, greater cost savings and fewer
adverse events than the standard dose. A previous open-label,
Figure 2. Mean HCV viral decline by IL28B genotype for the standard dose group (SDG) (Figure 2A) and the low-dose group (LDG)
(Figure 2B).
doi:10.1371/journal.pone.0048959.g002
Table 3. Rapid virological response (RVR) rate by treatment
group and IL28B genotype.
Treatment group IL28B genotype RVR. N (%) P
SDG CC 9 (40.9) 0.748
Non-CC 12 (44.4)
LDG CC 13 (38.2) 0.642
Non-CC 12 (35.3)
IL28B genotype Treatment group RVR. N (%) P
CC SDG 9 (40.9) 0.642
LDG 13 (38.2)
Non-CC SDG 12 (44.4) 0.221
LDG 12 (35.3)
Interleukin 28B (IL28B), rapid virological response (RVR), standard drug dose
group (SDG), low drug dose group (LDG).
doi:10.1371/journal.pone.0048959.t003
Low versus Standard-Dose of HCV Treatment
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single-arm pilot clinical trial involving 58 HCV/HIV co-infected
patients receiving low doses of Peg-IFN/RBV found that SVR
rates were 58.3% based on intention-to-treat [20]. The main
limitation of this study was the fact that it was not randomized but
a single-arm study whose results were compared with those
observed in earlier clinical trials The results of the pilot study
suggested that a lower Peg-IFN/RBV dose might be as effective as
the standard dose, so supporting the design of a randomized
controlled trial. There are no data however about the efficacy or
safety of standard Peg-IFN/RBV dose compared to a lower-than
standard dose.
To the best of our knowledge, this is the first study to compare
the efficacy of HCV viral clearance using low-dose and standard-
dose drug therapy in HIV/HCV co-infected patients in the first
weeks after treatment starts. Our findings suggest that the antiviral
activity of the lower Peg-IFN/RBV dose is weaker than with the
standard dose, which does not support equating the two for HIV/
HCV co-infected patients. Our results also suggest that HCV viral
decline during the first weeks of treatment would be dose-
dependent, although the mechanism responsible for the difference
is unknown.
In our study, we found no relation between IL28B genotype and
viral decline in either of the regimens evaluated. The positive effect
on treatment response associated with the IL28B-CC genotype has
only been observed in patients bearing genotype 1/4 [25,26]. In
fact, a previous study developed by our group reported that
variations in IL28B do not have a positive impact on HCV viral
decline in the first weeks after start of therapy using a standard
drug dose [3]. Nor did IL28B-CC have a positive effect on RVR
or SVR at standard or low drug doses in patients bearing genotype
3 [20,25].
Our study has several limitations. Firstly, our study is not a
randomized clinical trial, and the presence of significant bias
cannot therefore be ruled out. Secondly, due to the higher RVR
rate in HCV genotype 2/3 patients, our study did not have the
statistical power to detect differences in RVR rate by drug
treatment dose. Thirdly, our study looked at the impact of IL28B
by determining only SNP rs12979860, although the impact
observed for this is not expected to be different from the other
known IL28B SNP (rs8099917).
In conclusion, our results show that patients who received
135 mg/per week with a 800 mg/day ribavirin dose had less HCV
viral decline in the first weeks after treatment started than those
who received 180 mg/per week with a weight-adjusted ribavirin
dose. The implications of weaker HCV viral decline in terms of
treatment outcome are unknown, although it would be expected
for a weaker HCV decline to lead to a lower RVR and
consequently to a lower SVR. In order to resolve this point, our
findings provide justification for the design of a randomized
clinical trial to compare the specific efficacy endpoints of the two
Peg-IFN/RBV doses in HIV/HCV co-infected patients. Until
such a randomized clinical trial with these specific endpoints is
conducted, therefore, clinicians should be cautious about using
lower-than-standard Peg-IFN/RBV doses in HIV/HCV genotype
3 co-infected patients.
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